Press Releases

IGC-Pharma-Alzheimers-Equity-Analyst-Coverage-AGP (1)
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock. Raising P/T to $4.25” 
Read More →
IGC-Pharma-Alzheimers-Equity-Analyst-Coverage-AGP
IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the “Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results”
Read More →
IGC-Pharma-Alzheimers-AI-Dementia-Diagnostic
IGC Pharma Expands AI Platform with Advanced Diagnostic Model for Alzheimer’s and Dementia Detection  
Read More →
IGC-Pharma-Alzheimers-Lions-Mane-Turkey-tail-Longevity-Renew
IGC Pharma Expands Holiby™ Product Line with –Longevity’ and –Renew’ – Targeting the Multi-Billion-Dollar Anti-Aging Market  
Read More →
IGC-Pharma-Alzheimers-Reports-Fiscal Results
IGC Pharma Reports Third Quarter Fiscal 2025 Results  
Read More →
IGC-Pharma-Alzheimers-Ashwagandha-Elderberry-Immunity-Energy
IGC Pharma Expands into $75 Billion Wellness Market with the Launch of Holiby™    
Read More →
IGC-Pharma-Alzheimers-Nia-Prepare-Challenge
IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer’s Disease  
Read More →
IGC-Pharma-Alzheimers-Governor-Terry-Maculiffe-Advisor
IGC Pharma Appoints Former Virginia Governor Terry McAuliffe as Strategic Advisor
Read More →
IGC-Pharma-Alzheimers-Fireside-Capital-Markers
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets  
Read More →
tumbnail-IGCPharma-names-IGC-AD1-Phase-2-Clinical-Trial-for-Alzheimers-Agitation-CALMA-min
IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer’s Agitation CALMA and Expands Recruitment Strategy    
Read More →
IGC-Pharma-Alzheimer-JP-Morgan-Healthcare-Conference
IGC Pharma Announces Participation in BioPartnering @ JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025  
Read More →
IGC-Pharma-Alzheimer-Therapy-Cognitive-Pathology
IGC Pharma Advances IGC-AD1 as a Potential Alzheimer’s Therapy Addressing Cognitive Impairment and Underlying Disease Pathology  
Read More →
IGC Pharma-Phase2- Results-Cognitive-Benefits-Alzheimer-Th
IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer’s Treatment  
Read More →
IGC-Pharma-Alzheimer-Fiscal-Report-TN
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in its Alzheimer’s Pipeline
Read More →
IGC Pharma-IMS-Spotlight-Interview-Alzheimer-Weight-Loss-Therapies-TN
IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss Therapies
Read More →
IGC-Pharma-Two-Patients-Baycrest-Phase-2-Alzheimer
IGC Pharma Announces Patient Enrollment at Toronto’s Baycrest in Phase 2 Trial Investigating IGC-AD1
Read More →